LY9 and plasma cell myeloma: Recently, the SLAM receptor CD229/LY9 has been used as potential target for chimeric antigen receptor (CAR) T cell therapy in MM due to its strong and broader expression on the surface of BM plasma cells from MM and MGUS patients and on chemotherapy-resistant myeloma precursor cells (167–169).